40 results
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
11 Jun 24
Regulation FD Disclosure
9:15pm
development goals in its expected timeframes, risks related to adverse side effects, risks related to reliance on third party partners to conduct certain
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
goals so the Company continues to monitor these factors and events and the potential effects each may have on the Company’s business, financial
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
rate in effect as of December 31, 2022 (£1/$1.2103).
Amount shown reflects cash bonuses awarded for achievement of performance goals.
Amounts reflect … of performance goals determined in accordance with our annual bonus plan. We currently contribute to Dr. Scots-Knight’s Self-Invested Personal Pension Scheme
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
standards designed to assure the product’s continued safety, quality and purity. Under the goals and policies agreed to by the FDA under the Prescription … review designations within six months of the filing date as compared to ten months under its current review goals.
Fast track designation
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
17 Oct 23
Current report (foreign)
7:01am
projected development goals in its expected timeframes, risks related to adverse side effects, risks related to reliance on third party partners
6-K
EX-99.1
9uy3gdq
6 Jul 23
Ultragenyx Announces First Patients Dosed in Phase 3 Program
8:05am
6-K
EX-99.1
t7x feph4r8
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.2
ron0r
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
cfc2u07dp78vmehz1dy
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am